Halozyme beats, oks $1B buyback

 

Halozyme beats Q1 expectations and authorizes $1B share repurchase program

• Q1 2026 adjusted EPS $1.60 versus $1.54 expected, coming in above expectations.
• Q1 2026 revenue $376.7 million compared with $357.7 million forecast, also ahead of expectations.
• Maintains 2026 full-year guidance for EPS $7.75–$8.25 on revenue of $1.71–$1.81 billion.
• Share repurchase authorization totals $1B, with at least $400M of buybacks planned for this year.

https://finviz.com/quote?t=HALO&p=d